Blood Biomarkers As Outcome Measures in Inflammatory Neurologic Diseases

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2016 Oct 21

PMID 27757816

Citations 7

Authors

Nabil K El Ayoubi

Samia J Khoury

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system. Only a few biomarkers are available in MS clinical practice, such as cerebrospinal fluid oligoclonal bands and immunoglobulin index, serum anti-aquaporin 4 antibodies, and serum anti-John Cunningham virus antibodies. Thus, there is a significant unmet need for biomarkers to assess prognosis, response to therapy, or potential treatment complications. Here we describe emerging biomarkers that are in development, focusing on those from peripheral blood. There are several limitations in the process of discovery and validation of a good biomarker, such as the pathophysiological complexity of MS and the technical difficulties in globally standardizing methods for sampling, processing, and conserving biological specimens. In spite of these limitations, ongoing international collaborations allow the exploration of many interesting molecules and markers to validate diagnostic, prognostic, and therapeutic-response biomarkers.

Citing Articles

Post-translational modifications glycosylation and phosphorylation of the major hepatic plasma protein fetuin-A are associated with CNS inflammation in children.

Ricken F, Can A, Graber S, Hausler M, Jahnen-Dechent W PLoS One. 2022; 17(10):e0268592.

PMID: 36206263 PMC: 9544022. DOI: 10.1371/journal.pone.0268592.

A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis.

Barizzone N, Leone M, Pizzino A, Kockum I, Martinelli-Boneschi F, DAlfonso S J Pers Med. 2022; 12(9).

PMID: 36143216 PMC: 9501898. DOI: 10.3390/jpm12091430.

Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.

Ruder J, Dinner G, Maceski A, Berenjeno-Correa E, Muller A, Jelcic I Int J Mol Sci. 2022; 23(18).

PMID: 36142860 PMC: 9503241. DOI: 10.3390/ijms231810946.

Higher Serum Immunoglobulin G3 Levels May Predict the Development of Multiple Sclerosis in Individuals With Clinically Isolated Syndrome.

Trend S, Jones A, Cha L, Byrne S, Geldenhuys S, Fabis-Pedrini M Front Immunol. 2018; 9:1590.

PMID: 30057580 PMC: 6053531. DOI: 10.3389/fimmu.2018.01590.

Inflammation in CNS neurodegenerative diseases.

Stephenson J, Nutma E, van der Valk P, Amor S Immunology. 2018; 154(2):204-219.

PMID: 29513402 PMC: 5980185. DOI: 10.1111/imm.12922.

References

Szczucinski A, Losy J . Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand. 2007; 115(3):137-46. DOI: 10.1111/j.1600-0404.2006.00749.x. View

McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P . Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2015; 87(2):117-25. PMC: 4752634. DOI: 10.1136/jnnp-2015-311100. View

Kasper L, Shoemaker J . Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology. 2009; 74 Suppl 1:S2-8. DOI: 10.1212/WNL.0b013e3181c97c8f. View

Sharief M, Noori M, Douglas M, Semra Y . Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis. Eur J Neurol. 2002; 9(5):503-10. DOI: 10.1046/j.1468-1331.2002.00454.x. View

Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T . Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2015; 87(2):126-9. DOI: 10.1136/jnnp-2014-309690. View

Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A . CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. 2012; 19(4):436-42. PMC: 3652709. DOI: 10.1177/1352458512458010. View

Lv X, Jiang H, Liu Y, Lei X, Jiao J . MicroRNA-15b promotes neurogenesis and inhibits neural progenitor proliferation by directly repressing TET3 during early neocortical development. EMBO Rep. 2014; 15(12):1305-14. PMC: 4264933. DOI: 10.15252/embr.201438923. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

OConnor K, McLaughlin K, De Jager P, Chitnis T, Bettelli E, Xu C . Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007; 13(2):211-7. PMC: 3429369. DOI: 10.1038/nm1488. View

10.

Terzi M, Birinci A, Cetinkaya E, Onar M . Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand. 2007; 115(5):325-30. DOI: 10.1111/j.1600-0404.2007.00782.x. View

11.

Semra Y, Seidi O, Sharief M . Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol. 2002; 122(1-2):132-9. DOI: 10.1016/s0165-5728(01)00455-6. View

12.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J . Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler. 2015; 21(8):1013-24. DOI: 10.1177/1352458514568827. View

13.

Brickshawana A, Hinson S, Romero M, Lucchinetti C, Guo Y, Buttmann M . Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol. 2014; 13(8):795-806. PMC: 4144430. DOI: 10.1016/S1474-4422(14)70141-3. View

14.

Awad A, Hemmer B, Hartung H, Kieseier B, Bennett J, Stuve O . Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol. 2009; 219(1-2):1-7. DOI: 10.1016/j.jneuroim.2009.09.002. View

15.

Zipp F . Apoptosis in multiple sclerosis. Cell Tissue Res. 2000; 301(1):163-71. DOI: 10.1007/s004410000179. View

16.

Lassmann H . Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp Neurol. 2009; 225(1):2-8. DOI: 10.1016/j.expneurol.2009.10.009. View

17.

Wekerle H . Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis. 2008; 67 Suppl 3:iii56-60. DOI: 10.1136/ard.2008.098020. View

18.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177-89. PMC: 4515040. DOI: 10.1212/WNL.0000000000001729. View

19.

Azoulay D, Vachapova V, Shihman B, Miler A, Karni A . Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol. 2005; 167(1-2):215-8. DOI: 10.1016/j.jneuroim.2005.07.001. View

20.

Festa E, Hankiewicz K, Kim S, Skurnick J, Wolansky L, Cook S . Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler. 2009; 15(11):1271-9. DOI: 10.1177/1352458509107017. View